Cover Image
市场调查报告书

全球的个性化诊断(order made诊断)市场

World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)

出版商 Kalorama Information 商品编码 231620
出版日期 内容信息 英文 430 Pages
订单完成后即时交付
价格
本报告书已不再贩售
Back to Top
全球的个性化诊断(order made诊断)市场 World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
出版日期: 2012年03月01日 内容信息: 英文 430 Pages

本报告已在2018年07月02日停止出版

简介

本报告,调查分析临床检查上个性化诊断(order made诊断)的市场机会与将来潜在性,汇整个性化诊断的发展背景与所面临的限制・课题、疾病标的、现行以及开发中的检查・生物标记・诊断技术的各种动向、主要国家/地区的动向、主要业者的行动、策略建议等,由下列摘要形式阐述。

第1章 报告摘要

  • 简介
  • 调查范围・调查手法
  • 市场规模・成长率
  • 市场动向

第2章 简介

  • 背景
  • 2000年以后的发展:个性化医疗的限制与将来的展望
  • 风险与治疗的个性化
  • 个性化治疗薬:药剂・疫苗・其他
  • 个性化医疗的各种方面

第3章 策略课题:「COMMERCIALIZATION CONDUNDRUM(商业化的难题)」

  • 背景
  • 新检查的医疗报销
  • 医疗费用支付者的展望与方针
  • 法律规范上的课题与个性化分析
  • IVD或者CLIA、还是双方
  • 对医师的教育与医师的接受
  • 专利上的课题与个性化诊断的商业化
  • POC检查的展望

第4章 疾病标的

  • 背景
  • 生物标记的批准与有用性
  • 细胞色素P450与药物代谢
  • 乳癌的雌激素受体与黄体素受体
  • HER2过剩发现与贺癌平・泰嘉锭
  • 上皮成长因子受体(EGFR:Epidermal Growth Factor Receptor)
  • 大肠癌的KRAS突变与抗EGFR药
  • BRAF突变与癌症治疗药
  • UGT1A1基因变异体
  • 5-Flurouracil(5-FU)治疗药
  • PIK3CA基因变异体
  • KIF6基因变异体
  • ALK基因变异体

第5章 诊断技术

  • PCR型分析
  • 单一核甘酸多型性(SNP:Single Nucleotide Polymorphism)的基因型
  • 次世代定序
  • LDT的支配
  • 小型化・复合式分析
  • 癌症领域上复数的基因/生物标记的试验
  • 质谱仪
  • 奈米科技的角色
  • 蛋白质体学与生物标记的检测
  • 分子影像与个性化医疗
  • 情报技术

第6章 市场分析

  • 背景
  • 个性化诊断世界的市场机会
    • 美国
    • 欧洲
    • 日本
    • 其他
  • 医药品以及诊断相关业者间的契约
  • IVD相关业者以及CLIA实验室间的契约
  • 主要企业以及实验室
  • 癌症管理上的个性化医疗市场
    • 细胞组织型的检查
    • 血液标记
    • 循环肿瘤细胞
  • 传染病的个性化医疗市场
    • HIV
    • HBV
    • HCV
    • 院内传染病
  • 凝固疗法的个性化医疗市场
    • Warfarin
    • 血小板功能
  • 自我免疫疾病的个性化医疗市场
  • 心血管系统疾病的个性化医疗市场
  • CNS障碍的个性化医疗市场
  • 糖尿病的个性化医疗市场
  • 输血安全性部门的个性化医疗市场
  • 健康・美容部门的个性化医疗市场

第7章 结论・策略建议

第8章 企业档案数据

图表

目录
Product Code: KLI6640829

In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to looking at tests on the market currently, the report profiles key competitors and discusses trends important for understanding this much-discussed growth area for the diagnostic industry.

The concept of ‘Personalized Medicine’ currently, as seen by Kalorama clinical diagnostics industry analyst Shara Rosen, is somewhere between dream and road to reality. Fantastic promises have been made over the years in the press and reports of startup concerns. But slowly and surely, real revenues are appearing, and realistic models for future growth will be seen. Developments that are linked in the press to 'personalized medicine' are many and can at times be confusing. But there are several discovered biomarkers that are significant in diagnostic markets. Biomarkers discussed in the report include:

  • Cytochrome P450 and Drug Metabolism
  • Estrogen Receptor and Progesterone
  • Receptor Status for Breast Cancer
  • HER2 Overexpression and Herceptin and Tykerb
  • Epidermal Growth Factor Receptor (EGFR)
  • KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
  • BRAF Mutations and Cancer Therapy
  • UGT1A1 Genetic Variants
  • 5-Flurouracil Therapy
  • PIK3CA Genetic Variation
  • KIF6 Genetic Variation
  • ALK Genetic Variation

This is a highly active market. A special focus of the report is the amount of collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs. This report will profile scores of such companies operating in this market and estimate and forecast markets for personalized medicine technologies in the following categories:

  • World Market for Personalized Medicine Diagnostics by Disease (Cardiovascular, Nutritional Conditions, Diabetes, CNS,
  • Blood Transfusion)
  • World Market for Tissue-based Tests Personalized Medicine Diagnostics
  • World Market for Blood Markers Personalized Medicine Diagnostics
  • World Market for Circulating Tumor Cells Personalized Medicine Diagnostics
  • World Market for HIV Personalized Medicine Diagnostics
  • World Market for HBV Personalized Medicine Diagnostics
  • World Market for HCV Personalized Medicine Diagnostics
  • World Market for Hospital Acquired Infection Personalized Medicine Diagnostics
  • World Market for Warfarin Personalized Medicine Diagnostics
  • World Market for Platelet Function Personalized Medicine Diagnostics

Companies profiled in this report include:

The Major IVD Companies

  • Abbott Diagnostics Beckman Coulter Inc.
  • Becton,
  • Dickinson and Company
  • bioMerieux Inc.
  • Celera Corporation
  • Cepheid
  • China Medical Technologies
  • Dako Denmark A/S
  • Fujirebio Diagnostics, Inc.
  • GE Healthcare
  • Gen-Probe Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • PerkinElmer Inc.
  • Phadia AB
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Ventana Medical Systems Inc.
  • Wako Diagnostics

Participants

  • 20/20 GeneSystems, Inc.
  • 23andMe
  • Accumetrics
  • AdvanDx, Inc.
  • Affymetrix, Inc.
  • Agendia BV
  • Almac Diagnostics
  • AltheaDx, Inc.
  • Ambry Genetics
  • Arrayit Corporation
  • ARUP Laboratories
  • AssureRx Health, Inc.
  • Asuragen, Inc.
  • Autogenomics Inc.
  • BG Medicine, Inc.
  • Biocare Medical, LLC
  • Biocartis SA
  • Biocept, Inc.
  • BioCurex, Inc.
  • Biodesix, Inc.
  • BioReference Laboratories, Inc.
  • BioServe
  • bioTheranostics
  • Clarient Inc.
  • CombiMatrix Molecular Diagnostics, Inc.
  • Corgenix Medical Corporation
  • Cylex, Inc.
  • Dana Farber Cancer Institute
  • DeCode Genetics
  • DxS Ltd.
  • DxTerity Diagnostics Inc.
  • Enzo Clinical Labs
  • Epigenomics AG
  • Euroimmun AG
  • Genelex Corporation
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Genzyme Genetics
  • Illumina Inc.
  • Interleukin Genetics, Inc.
  • Ipsogen SA
  • Knome, Inc.
  • Lab21 Limited
  • Laboratory Corporation of America Holdings
  • LabCorp)
  • Life Technologies Corporation
  • Mayo Medical Laboratories
  • MDxHealth SA
  • Monogram Biosciences, Inc.
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • Navigenics
  • Pathway Genomics
  • Pathwork Diagnostics, Inc.
  • Power3 Medical Products, Inc.
  • Precision Therapeutics
  • Predictive Biosciences
  • Progenika Inc.
  • Prometheus Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Response Genetics, Inc.
  • Rosetta Genomics
  • Rules-Based Medicine, Inc.
  • Saladax Biomedical, Inc.
  • Sequenom, Inc.
  • TGen (The Translational Genomics
  • Research Institute)
  • TrimGen Corporation
  • TrovaGene, Inc.
  • Veridex, LLC
  • Vermillion Inc.
  • Virco BVBA
  • XDx, Inc.

The Newcomers

  • Abkine Pharmaceuticals
  • Accelerated Medical Diagnostics, LLC
  • Advanced Biological Laboratories
  • Affomix Corporation
  • Ahram Biosystems, Inc.
  • Alacris Theranostics GmbH
  • Amoy Diagnostics Co. Ltd.
  • ApoCell, Inc.
  • Atossa Genetics, Inc.
  • Augurex Life Sciences Corp.
  • Biofortuna Ltd.
  • Biomarker Factory, The
  • BioMarker Strategies
  • Biomedical Diagnostics
  • BlackBio S.L.
  • Bostwick Laboratories
  • Cancer Genetics, Inc.
  • Cancer Treatment Centers of America
  • CancerGuide Diagnostics, Inc.
  • CardioDx, Inc.
  • Caris Life Sciences
  • Chronix Biomedical
  • Crescendo Bioscience, Inc.
  • Critical Diagnostics
  • Curidium Medica Limited
  • CvergenX
  • DermaGenoma, Inc.
  • DiaTech Oncology
  • Eutropics Pharmaceuticals
  • Everist Genomics
  • Evotec AG
  • Exosome Diagnostics Inc.
  • Foundation Medicine Inc.
  • GeneNews Limited
  • Genetic Technologies Limited
  • GenMark Diagnostics Inc.
  • Genomas
  • Genomind, LLC
  • GenoVive LLC
  • GMS Biotech
  • Inostics GmbH
  • Insight Genetics
  • IntegraGen SA
  • IRIS International, Inc.
  • Iverson Genetic Diagnostics, Inc.
  • Linkage Biosciences, Inc.
  • Med BioGene, Inc.
  • Medco Health Solutions Inc.
  • Metamark Genetics, Inc.
  • Mira Dx
  • Molecular Response
  • MolecularMD Corp.
  • Nanostring Technologies, Inc.
  • NaturalNano, Inc.
  • NewGene
  • NobleGen Biosciences
  • Nodality Inc.
  • Novartis Molecular Diagnostics
  • Nuvera Biosciences, Inc.
  • On-Q-ity
  • Orion Genomics
  • OvaGene Oncology, Inc.
  • Pacific Edge Biotechnology Limited
  • Pathogenica
  • Pharmigene
  • Pinpoint Genomics, Inc.
  • Population Diagnostics, Inc.
  • Proctor & Gamble
  • Psynomics Incorporated
  • Radient Pharmaceuticals Corporation
  • ScreenCell
  • Scripps Health
  • Seegene Inc.
  • Signal Genetics
  • Signature Diagnostics AG
  • Sirius Genomics
  • Skyline Diagnostics B.V.
  • Spartan Bioscience Inc.
  • SureGene, LLC
  • TcLand Expression SA
  • Transgenomic, Inc.
  • ViennaLab Diagnostics GmbH

Information Technology Specialists

  • CLC bio
  • CollabRx
  • Definiens
  • Dell Healthcare and Life Sciences
  • DNA Direct
  • GenomeQuest Inc.
  • HolGenTech Inc.
  • IDBS
  • MediSapiens Ltd.
  • Partners HealthCare Center for Personalized
  • Genetic Medicine
  • Selventa
  • Sophic Systems Alliance

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Market Trends

CHAPTER TWO: INTRODUCTION

  • Background
  • Developments since 2000 - Limitations of Personalized Medicine and Future Prospects
  • Personalizing risk and therapies
  • Personalized Therapies - drugs, vaccines and others
  • Aspects of Personalized Medicine
    • Screening for Disease Risk
    • Early diagnosis
    • Therapy Selection and Monitoring

CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”

  • Background
  • Reimbursement of Novel Tests
    • United States
    • Europe
  • Payor Perspectives and Policies
  • Regulatory Issues and Personalized Medicine Assays
    • United States
    • Europe
  • IVD vs CLIA or Both
  • Physician Education and Acceptance
  • Patent Issues and Commercializing Personalized Diagnostics
  • Prospects for POC Testing

CHAPTER FOUR: DISEASE TARGETS

  • Background
  • Biomarker Validation and Utility
  • Cytochrome P450 and Drug Metabolism
  • Estrogen Receptor and Progesterone Receptor Status for Breast Cancer
  • HER2 Overexpression and Herceptin and Tykerb
  • Epidermal Growth Factor Receptor (EGFR)
  • KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
  • BRAF Mutations and Cancer Therapy
  • UGT1A1 Genetic Variants
  • 5-Flurouracil Therapy
  • PIK3CA Genetic Variation
  • KIF6 Genetic Variation
  • ALK Genetic Variation

CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES

  • PCR-based assays
  • Single nucleotide polymorphism (SNP) genotyping
  • Next-gen sequencing
  • LDTs reign
  • Miniaturization and Multiplexed Assays
  • Multi-Gene/Biomarker Tests in Oncology
  • Mass Spectroscopy
  • Role of Nanobiotechnology
  • Proteomics and Biomarker Detection
  • Molecular Imaging and Personalized Medicine
  • Information Technology

CHAPTER SIX: MARKET ANALYSIS

  • Background
  • Worldwide Opportunities for Personalized Medicine Diagnostics
    • The United States
    • Europe
    • Japan
    • ROW
  • Agreements between Pharmaceutical and Diagnostic Companies
  • Agreements between IVD companies and CLIA labs
  • Major Companies and Labs
  • The Market for Personalized Medicine in Cancer Management
    • Tissue-based Tests
    • Blood Markers
    • Circulating Tumor Cells
  • The Market for Personalized Medicine in Infectious Diseases
    • HIV
    • HBV
    • HCV
    • Hospital Acquired Infections
  • The Market for Personalized Medicine in Coagulation Therapy
    • Warfarin
    • Platelet Function
  • The Market for Personalized Medicine in Autoimmune Diseases
  • The Market for Personalized Medicine in Cardiovascular Diseases
  • The Market for Personalized Medicine in CNS Disorders
  • The Market for Personalized Medicine in Diabetes
  • The Market for Personalized Medicine in Blood Transfusion Safety
  • The Market for Personalized Medicine in Nutrition and Beauty

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

CHAPTER EIGHT: COMPANY PROFILES

The Major IVD Companies

  • Abbott Diagnostics Beckman Coulter Inc. Becton,
  • Dickinson and Company
  • bioMérieux Inc.
  • Celera Corporation
  • Cepheid
  • China Medical Technologies
  • Dako Denmark A/S
  • Fujirebio Diagnostics, Inc.
  • GE Healthcare
  • Gen-Probe Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • PerkinElmer Inc.
  • Phadia AB
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Ventana Medical Systems Inc.
  • Wako Diagnostics

Participants

  • 20/20 GeneSystems, Inc.
  • 23andMe
  • Accumetrics
  • AdvanDx, Inc.
  • Affymetrix, Inc.
  • Agendia BV
  • Almac Diagnostics
  • AltheaDx, Inc.
  • Ambry Genetics
  • Arrayit Corporation
  • ARUP Laboratories
  • AssureRx Health, Inc.
  • Asuragen, Inc.
  • Autogenomics Inc.
  • BG Medicine, Inc.
  • Biocare Medical, LLC
  • Biocartis SA
  • Biocept, Inc.
  • BioCurex, Inc.
  • Biodesix, Inc.
  • BioReference Laboratories, Inc.
  • BioServe
  • bioTheranostics
  • Clarient Inc.
  • CombiMatrix Molecular Diagnostics, Inc.
  • Corgenix Medical Corporation
  • Cylex, Inc.
  • Dana Farber Cancer Institute
  • DeCode Genetics
  • DxS Ltd.
  • DxTerity Diagnostics Inc.
  • Enzo Clinical Labs
  • Epigenomics AG
  • Euroimmun AG
  • Genelex Corporation
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Genzyme Genetics
  • Illumina Inc.
  • Interleukin Genetics, Inc.
  • Ipsogen SA
  • Knome, Inc.
  • Lab21 Limited
  • Laboratory Corporation of America Holdings (LabCorp)
  • Life Technologies Corporation
  • Mayo Medical Laboratories
  • MDxHealth SA
  • Monogram Biosciences, Inc.
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • Navigenics
  • Pathway Genomics
  • Pathwork Diagnostics, Inc.
  • Power3 Medical Products, Inc.
  • Precision Therapeutics
  • Predictive Biosciences
  • Progenika Inc.
  • Prometheus Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Response Genetics, Inc.
  • Rosetta Genomics
  • Rules-Based Medicine, Inc.
  • Saladax Biomedical, Inc.
  • Sequenom, Inc.
  • TGen (The Translational Genomics Research Institute)
  • TrimGen Corporation
  • TrovaGene, Inc.
  • Veridex, LLC
  • Vermillion Inc.
  • Virco BVBA
  • XDx, Inc.

The Newcomers

  • Abkine Pharmaceuticals
  • Accelerated Medical Diagnostics, LLC
  • Advanced Biological Laboratories
  • Affomix Corporation
  • Ahram Biosystems, Inc.
  • Alacris Theranostics GmbH
  • Amoy Diagnostics Co. Ltd.
  • ApoCell, Inc.
  • Atossa Genetics, Inc.
  • Augurex Life Sciences Corp.
  • Biofortuna Ltd.
  • Biomarker Factory, The
  • BioMarker Strategies
  • Biomedical Diagnostics
  • BlackBio S.L.
  • Bostwick Laboratories
  • Cancer Genetics, Inc.
  • Cancer Treatment Centers of America
  • CancerGuide Diagnostics, Inc.
  • CardioDx, Inc.
  • Caris Life Sciences
  • Chronix Biomedical
  • Crescendo Bioscience, Inc.
  • Critical Diagnostics
  • Curidium Medica Limited
  • CvergenX
  • DermaGenoma, Inc.
  • DiaTech Oncology
  • Eutropics Pharmaceuticals
  • Everist Genomics
  • Evotec AG
  • Exosome Diagnostics Inc.
  • Foundation Medicine Inc.
  • GeneNews Limited
  • Genetic Technologies Limited
  • GenMark Diagnostics Inc.
  • Genomas
  • Genomind, LLC
  • GenoVive LLC
  • GMS Biotech
  • Inostics GmbH
  • Insight Genetics
  • IntegraGen SA
  • IRIS International, Inc.
  • Iverson Genetic Diagnostics, Inc.
  • Linkage Biosciences, Inc.
  • Med BioGene, Inc.
  • Medco Health Solutions Inc.
  • Metamark Genetics, Inc.
  • Mira Dx
  • Molecular Response
  • MolecularMD Corp.
  • Nanostring Technologies, Inc.
  • NaturalNano, Inc.
  • NewGene
  • NobleGen Biosciences
  • Nodality Inc.
  • Novartis Molecular Diagnostics
  • Nuvera Biosciences, Inc.
  • On-Q-ity
  • Orion Genomics
  • OvaGene Oncology, Inc.
  • Pacific Edge Biotechnology Limited
  • Pathogenica
  • Pharmigene
  • Pinpoint Genomics, Inc.
  • Population Diagnostics, Inc.
  • Proctor & Gamble
  • Psynomics Incorporated
  • Radient Pharmaceuticals Corporation
  • ScreenCell
  • Scripps Health
  • Seegene Inc.
  • Signal Genetics
  • Signature Diagnostics AG
  • Sirius Genomics
  • Skyline Diagnostics B.V.
  • Spartan Bioscience Inc.
  • SureGene, LLC
  • TcLand Expression SA
  • Transgenomic, Inc.
  • ViennaLab Diagnostics GmbH

Information Technology Specialists

  • CLC bio
  • CollabRx
  • Definiens
  • Dell Healthcare and Life Sciences
  • DNA Direct
  • GenomeQuest Inc.
  • HolGenTech Inc.
  • IDBS
  • MediSapiens Ltd.
  • Partners HealthCare Center for Personalized Genetic Medicine
  • Selventa
  • Sophic Systems Alliance

LIST OF TABLES

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1. Exchange Rate Fluctuations, 2005-2010
  • Table 1-2. Worldwide Personalized Medicine Test Sales, 2011-2016

CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”

  • Table 3-1. Selected Company Sponsored Certified Labs
  • Table 3-2. Proposed Palmetto non-coverage tests
  • Table 3-3. Selected LDT Companies Cited by the FDA
  • Table 3-4. Selected POC-appropriate Systems

CHAPTER FOUR: DISEASE TARGETS

  • Table 4-1. Selected Drug/Biomarker Targets in the U.S.
  • Table 4-2. Selected drugs that require PMx testing in Europe
  • Table 4-3. Selected Commercial CYP450 Warfarin Tests
  • Table 4-4. Selected drugs associated with CYP450 metabolism
  • Table 4-5. Selected innovations in EFGR tests
  • Table 4-6. Selected KRAS test innovations
  • Table 4-7. Selected BRAF gene test innovations
  • Table 4-8. Selected PIK3CA mutation test innovations
  • Table 4-9. Selected Innovations in CTC Systems
  • Table 4-10. Selected Live Cell Assays

CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES

  • Table 5-1. Selected Novel Nucleic Acid Testing Platforms, 2008-2011
  • Table 5-2. Major Sequencing Platforms
  • Table 5-3. Selected innovations in sequencing
  • Table 5-4. Selected Company Sponsored Certified Labs
  • Table 5-5. Selected LDT Service Provider Revenues, 2007-2011
  • Table 5-6. Selected PMx tests using microarrays
  • Table 5-7. Selected Gene Expression Tests
  • Table 5-8. Selected innovations in mass spectroscopy for personalized medicine
  • Table 5-9. Selected novel biomarkers under investigation
  • Table 5-10. Selected Innovations in Protein Biomarkers
  • Table 5-11. Selected companies involved in chromosomal analysis of cells
  • Table 5-12. Selected test digital platform innovations
  • Table 5-13. Selected blood-based tests in personalized medicine
  • Table 5-14. IT solutions for personalized medicine

CHAPTER SIX: MARKET ANALYSIS

  • Table 6-1. Worldwide Commercial Personalized Medicine Test Sales, by category
  • Table 6-2. Market Penetration Of PMx Tests, by geographic area, 2011-2016
  • Table 6-3. Selected Agreements between IVD Companies and Lab Services
  • Table 6-4. Worldwide Sales of PMx Tests for Cancer, by category, 2011-2016
  • Table 6-5. Major protein and molecular markers used in tissue staining
  • Table 6-6. Selected Pharmacodiagnostic Histology Tests
  • Table 6-7. Selected chromosome-based cancer tests and services
  • Table 6-8. Selected HPV tests
  • Table 6-9. Selected Tumor Marker Innovations, 2008-2011
  • Table 6-10. Selected Innovations in Molecular PMx Tests for Cancer
  • Table 6-11. PMx Test Sales for Infectious Diseases, worldwide, 2011-2016
  • Table 6-12. Selected PMx tests for infectious diseases
  • Table 6-13. Selected commercial MDR-TB test kits
  • Table 6-14. Selected molecular PMx coagulation tests
  • Table 6-15. Selected innovations in PMx testing for autoimmune diseases
  • Table 6-16. Selected IVD markers of CVD
  • Table 6-17. Worldwide PMx product sales for CVD, by category, 2011-2016
  • Table 6-18. Selected Cardiac Marker Innovations, 2008-2011
  • Table 6-19. Selected innovations in genetic tests for CVD
  • Table 6-20. Selected innovations in personalized tests for CNS diseases
Back to Top